PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 297 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 9.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,630,979 | -6.4% | 53,161 | +22.2% | 0.00% | 0.0% |
| Q2 2023 | $1,742,766 | +51.5% | 43,493 | +54.3% | 0.00% | 0.0% |
| Q1 2023 | $1,150,515 | -8.8% | 28,192 | -13.7% | 0.00% | 0.0% |
| Q4 2022 | $1,261,041 | -18.6% | 32,661 | +12.2% | 0.00% | 0.0% |
| Q3 2022 | $1,549,000 | -6.7% | 29,120 | +2.2% | 0.00% | 0.0% |
| Q2 2022 | $1,661,000 | -56.1% | 28,481 | -42.6% | 0.00% | -50.0% |
| Q1 2022 | $3,786,000 | +40.7% | 49,602 | +10.9% | 0.00% | +100.0% |
| Q4 2021 | $2,691,000 | -19.9% | 44,724 | -25.5% | 0.00% | -50.0% |
| Q3 2021 | $3,361,000 | +11.4% | 60,020 | +20.6% | 0.00% | 0.0% |
| Q2 2021 | $3,018,000 | +67.2% | 49,750 | +93.2% | 0.00% | +100.0% |
| Q1 2021 | $1,805,000 | -17.2% | 25,755 | -29.3% | 0.00% | 0.0% |
| Q4 2020 | $2,179,000 | +16.9% | 36,410 | +17.5% | 0.00% | 0.0% |
| Q3 2020 | $1,864,000 | -23.7% | 30,998 | -33.4% | 0.00% | -50.0% |
| Q2 2020 | $2,443,000 | +125.2% | 46,543 | +43.8% | 0.00% | +100.0% |
| Q1 2020 | $1,085,000 | -48.0% | 32,363 | -29.7% | 0.00% | 0.0% |
| Q4 2019 | $2,086,000 | +35.5% | 46,043 | +13.9% | 0.00% | 0.0% |
| Q3 2019 | $1,539,000 | -33.2% | 40,413 | -23.7% | 0.00% | 0.0% |
| Q2 2019 | $2,304,000 | +74.1% | 52,955 | +52.3% | 0.00% | 0.0% |
| Q1 2019 | $1,323,000 | -39.2% | 34,764 | -31.3% | 0.00% | -50.0% |
| Q4 2018 | $2,175,000 | -52.8% | 50,568 | -46.0% | 0.00% | -50.0% |
| Q3 2018 | $4,607,000 | +186.0% | 93,716 | +86.5% | 0.00% | +300.0% |
| Q2 2018 | $1,611,000 | -11.0% | 50,261 | -13.5% | 0.00% | 0.0% |
| Q1 2018 | $1,810,000 | -27.9% | 58,119 | +5.6% | 0.00% | -50.0% |
| Q4 2017 | $2,512,000 | -14.0% | 55,056 | -29.2% | 0.00% | 0.0% |
| Q3 2017 | $2,921,000 | -42.6% | 77,817 | -27.1% | 0.00% | -50.0% |
| Q2 2017 | $5,093,000 | +636.0% | 106,781 | +602.9% | 0.00% | – |
| Q1 2017 | $692,000 | -4.4% | 15,191 | -32.2% | 0.00% | – |
| Q4 2016 | $724,000 | -71.9% | 22,414 | -70.3% | 0.00% | -100.0% |
| Q3 2016 | $2,581,000 | +912.2% | 75,441 | +897.9% | 0.00% | – |
| Q2 2016 | $255,000 | -87.2% | 7,560 | -79.8% | 0.00% | -100.0% |
| Q1 2016 | $1,985,000 | +29.1% | 37,460 | +87.0% | 0.00% | 0.0% |
| Q4 2015 | $1,538,000 | +26.9% | 20,032 | -32.1% | 0.00% | +100.0% |
| Q3 2015 | $1,212,000 | -46.7% | 29,497 | -8.3% | 0.00% | -50.0% |
| Q2 2015 | $2,274,000 | -19.4% | 32,164 | +1.3% | 0.00% | -33.3% |
| Q1 2015 | $2,822,000 | +53.9% | 31,764 | +53.6% | 0.00% | +50.0% |
| Q4 2014 | $1,834,000 | +786.0% | 20,673 | +866.9% | 0.00% | – |
| Q3 2014 | $207,000 | +21.8% | 2,138 | +15.8% | 0.00% | – |
| Q2 2014 | $170,000 | -68.0% | 1,846 | -75.7% | 0.00% | -100.0% |
| Q1 2014 | $531,000 | -33.5% | 7,595 | -45.4% | 0.00% | 0.0% |
| Q4 2013 | $799,000 | +152.1% | 13,909 | +111.2% | 0.00% | – |
| Q3 2013 | $317,000 | +1661.1% | 6,587 | +1018.3% | 0.00% | – |
| Q2 2013 | $18,000 | – | 589 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |